How much weight can I lose using Wegovy?

What STEP 1 actually tells us about Wegovy results

The STEP 1 trial is the anchor. Over 68 weeks, adults with obesity or overweight and at least one weight-related condition lost an average of roughly 15% of their starting body weight on semaglutide 2.4mg, compared with under 3% on placebo. To translate that into everyday terms: someone starting at 100kg could expect to lose around 15kg on average across the trial period, with a substantial proportion of participants losing considerably more.

Results at individual doses vary, and the titration journey matters. The treatment begins at 0.25mg and steps up gradually over months — what the early doses contribute is quite different from what the maintenance dose achieves. There is also now a higher 7.2mg dose, approved by the MHRA in April 2026 for adults with a BMI of 30 or above, with trials reporting average losses of around 20.7% over 72 weeks at that dose. That is a meaningful narrowing of the gap with tirzepatide, though the right treatment for any individual is a clinical decision.

One thing the numbers cannot capture: individual variation is wide. A question our prescribers hear most weeks is some version of "but what will I actually lose?", and the honest answer is that the trial averages are the best guide available, not a guarantee. Biology, adherence, diet, activity and how well the dose is tolerated all shift the outcome, and if you want to dig into what the full maintenance dose of 2.4mg typically delivers the evidence is set out in detail. You can also explore a fuller breakdown of what Wegovy results look like across different groups for more detail on the range.

How UK private pricing for Wegovy is structured, and what headline costs leave out

Private Wegovy pricing in the UK is set per pen, which corresponds to a month of treatment at any given dose. The cost varies by dose and by provider. Since Eli Lilly's price increase on Mounjaro in September 2025 drew attention to the GLP-1 market more broadly, private list prices for weight-loss injectables have been widely reported as ranging from roughly £149 to £375 a month depending on the medicine, the dose and the clinic. Those figures are indicative, not universal.

What the headline number often does not include is where the real cost difference sits. Many private providers charge separately for the clinical consultation, the prescription fee, delivery, and any dose-review or aftercare support. A lower per-pen price can still result in a higher total spend once those items are added. It is worth asking any provider what is covered before comparing numbers. A full breakdown of how Wegovy private pricing works covers this in more detail.

At nume, we are deliberately not the cheapest option, and that is a considered position. One transparent price covers the consultation, prescription, treatment, next-working-day delivery and 7-day priority aftercare. No subscription, no auto-renewal, and no add-on fees discovered at checkout. Current treatment pricing is shown on our treatment page; we do not print per-pen prices in body copy.

Why weight lost matters more than price saved, and what to check before buying

For a prescription medicine, the cheapest listing answers the wrong question. Wegovy is a Prescription-Only Medicine. The law requires a clinical assessment before any legitimate supply, meaning a qualified prescriber reviews your health history, checks for contraindications, and decides whether the medicine is suitable for you. That process exists because GLP-1 medicines are not risk-free. The NHS semaglutide page lists the side effects and conditions that require extra caution; a good prescriber addresses those before handing over a pen.

Counterfeit weight-loss pens are a documented UK problem. The MHRA has seized large quantities of fake injectable weight-loss medicines sold online, some of which contained insulin rather than the stated active ingredient. The safest check: any online pharmacy supplying POMs legally must appear on the GPhC register. You can verify any provider (including us) at the GPhC register (premises number 9012878). Sellers offering these medicines without a prescription or at prices far below the market are a clinical red flag, not a bargain.

The right metric for a weight-loss medicine is not the cheapest listed price, it is whether you receive genuine, clinically supervised treatment through a regulated supply chain, with a prescriber who actually looks at your case. That is what determines how much weight you can safely lose using Wegovy, and how you do it without risk. If you want to understand what a realistic loss trajectory looks like before your consultation, our clinical content covers the evidence plainly.

The Wegovy overview page covers the medicine, licensing and access options in full. And if you want to explore treatment options more broadly before committing to anything, our weight-loss treatment overview is a good place to start. Check your eligibility with a free consultation when you are ready.